External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Infectious Disease IDW 2023
Roche and Genentech at

IDW 2023

October 11 - October 15
Boston, USA
idweek.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Oct 12 / Roche and Genentech
Cost-effectiveness of baloxavir marboxil▼ vs oseltamivir or no treatment for the management of influenza in the United States
A real-world evidence driven cost-effectiveness model was developed to evaluate antiviral treatment with baloxavir▼ compared with oseltamivir or no treatment in the US in otherwise healthy and high-risk individuals. The model showed that baloxavir▼ is cost-effective vs oseltamivir or no treatment from a US payer perspective.
Infectious Disease Influenza Virus Infection IDW-2023

Sign up or login to unlock the full suite of MEDICALLY features
Oct 12 / Roche and Genentech
Household Flu Transmission and Healthcare Resource Use among Patients Treated with Baloxavir▼ versus Oseltamivir for Influenza: An Outpatient Prospective Survey in the United States
This poster describes a prospective electronic survey that reports the incidence of household transmission and healthcare resource utilization in patients with influenza treated with baloxavir▼ vs oseltamivir.
Infectious Disease Influenza Virus Infection IDW-2023

Sign up or login to unlock the full suite of MEDICALLY features
Oct 11 / Roche
Development of a Prototype Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) Assay for use on the cobas 5800/6800/8800 System Utility Channel
Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) is recognized as an urgent/critical antimicrobial resistant threat by the Centers for Disease Control and Prevention and World Health Organization. This poster describes a prototype assay for the rapid detection of CRABC in hospital-acquired pneumonia/ventilator-associated pneumonia or bloodstream infections.
Infectious Disease Antimicrobial resistance Bacterial Infection IDW-2023
04:15 PM
Duration 1hr Boston, USA
Development of a Prototype Carbapenem-Resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) Assay for use on the cobas 5800/6800/8800 System Utility Channel
Sorenson NM, Nguyen H, Moghaddasi A, Sathish A, Somanathan I, Jia L, Lin P, Zhuang X, Lam C, Lee BP, Cady KC
Infectious Disease | Antimicrobial resistance - Bacterial Infection

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 1hr Boston, USA
Household Flu Transmission and Healthcare Resource Use among Patients Treated with Baloxavir▼ versus Oseltamivir for Influenza: An Outpatient Prospective Survey in the United States
Best J, Sadeghi M, Sun X, Seetasith A, Albensi L, Joshi S, Zervos M
Infectious Disease | Influenza Virus Infection

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 1hr Boston, USA
Cost-effectiveness of baloxavir marboxil▼ vs oseltamivir or no treatment for the management of influenza in the United States
Kommandantvold S, Chang S, Surinach A, Yau V, Best J, Zaraket H, Zhou H Blanchet-Zumofen M
Infectious Disease | Influenza Virus Infection

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.